Abstract:Abstract Background: Gastric cancer (GC) is the second most common cancer in Japan in terms of incidence and the third most common in terms of deaths. The onset and progression of cancer are generally suppressed by the action of immune cells, which is an inflammatory response. MDSCs are thought to promote cancer progression and invasion by suppressing the function of immune cells, making them potential therapeutic and diagnostic targets. We measured MDSCs in GC patients and observed more monocyte-derived MDSCs in peripheral blood in advanced GC than in early GC. However, granulocyte-derived MDSCs showed no difference in GC progression when markers for classical MDSCs were used. We considered that granulocyte-derived MDSCs were much more abundant than monocyte-derived MDSCs in peripheral blood and were involved in cancer progression. We hypothesized that we had a new granulocyte-derived marker for advanced GC that did not show differences in classical markers, but may have different functions, and aimed to identify a novel subset that may be a therapeutic and diagnostic target. Method: For GC patients, we used heparin blood samples provided by patients who consented to Juntendo University. We analyzed the expression of various cell surface proteins against populations of CD33high, CD66bhigh, and HLA-DRlow as classical markers of MDSCs derived from granulocytes of GC patients using FACS (Melody). MDSCs were isolated by a cell sorter and used for experiments such as RNA-Seq. Novel markers and involved cytokines were quantified in plasma components by cytometric bead array. Result: The chemokine receptors CCR2, CCR5, CXCR4, and CXCR5 were highly expressed in MDSCs of advanced GC patients. The ability to suppress T-cell activation was also found to be stronger in MDSCs with advanced GC. In addition, IL-10 produced by MDSCs was also more abundant in the plasma of patients with advanced GC, as well as chemokines according to chemokine receptors. Conclusion: The high expression of chemokine receptors on MDSCs in advanced GC may indicate that chemokines produced at the cancer site facilitate the migration of MDSCs. These novel subsets of MDSCs found in advanced GC suggest that they may be new therapeutic targets. Citation Format: Suguru Yamauchi, Takumi Iwasawa, Tomoaki Ito, Malcom V. Brock, Tetsu Fukunaga, Hajime Orita, Kazunori Kato. Analysis of MDSCs as a diagnostic and therapeutic target for gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5958.

CD45+CD33lowCD11bdim myeloid-derived suppressor cells suppress CD8+ T cell activity via the IL-6/IL-8-arginase I axis in human gastric cancer

Subtypes of MDSCs in Mechanisms and Prognosis of Gastric Cancer and Are Inhibited by Epirubicin and Paclitaxel.

Increased tumor-infiltrating CD45RA − CCR7 − regulatory T-cell subset with immunosuppressive properties foster gastric cancer progress

Increased Circulating GrMyeloid-derived Suppressor Cells Correlated with Tumor Burden and Survival in Locally Advanced Cervical Cancer Patient

Interleukin 33 in Tumor Microenvironment is Crucial for the Accumulation and Function of Myeloid-Derived Suppressor Cells

PMN-MDSCs Accumulation Induced by CXCL1 Promotes CD8+ T Cells Exhaustion in Gastric Cancer.

[The Number of Myeloid-Derived Suppressor Cells in the Peripheral Blood and Tumor Tissues in Patients with Gastric Cancer and Its Clinical Significance].

Exosomal PD-L1 induces MDSCs accumulation through IL-6/STAT3 pathway in gastric cancer

Abstract 5958: Analysis of MDSCs as a diagnostic and therapeutic target for gastric cancer

The expansion of MDSCs induced by exosomal PD-L1 promotes the progression of gastric cancer

Circulating and tumor-infiltrating arginase 1-expressing cells in gastric adenocarcinoma patients were mainly immature and monocytic Myeloid-derived suppressor cells

Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway.

Increased myeloid-derived suppressor cells in patients with myelodysplastic syndromes suppress CD8+ T lymphocyte function through the STAT3-ARG1 pathway

Altered phenotypic and functional characteristics of CD3+CD56+ NKT-like cells in human gastric cancer.

Circulating Myeloid-Derived Suppressor Cells in Patients with Pancreatic Cancer.

Expression and clinical significance of peripheral monocytic myeloid-derived suppressor cells in patients with gastric cancer

CD8(+) T Cells That Produce Interleukin-17 Regulate Myeloid-Derived Suppressor Cells and Are Associated with Survival Time of Patients with Gastric Cancer.

Ascites-derived IL-6 and IL-10 synergistically expand CD14 + HLA-DR -/low myeloid-derived suppressor cells in ovarian cancer patients.

Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer

MDSC (myeloid-derived suppressor cells) is an important immunosuppressing factor and functionally related with VEGF and IL-17 in patients with gastrointestinal cancer

Relationship of myeloid-derived suppressor cells (MDSC) and immune suppression, nutritional impairment, and inflammatory markers in patients with gastrointestinal cancer.